Evaluation of the effects of the triple angiokinase inhibitor BIBF 1120 on tumor vasculature in a phase I clinical trial using Dynamic Contrast-Enhanced MRI (DCE-MRI)
Stefanic M, de Rossi L, Hennig J, Strecker R, Mross K
Boehringer-Ingelheim Pharma GmbH & CO KG
DCE-MRI using an IR trueFISP protocol was applied in a clinical phase I trial of the novel triple angiokinase inhibitor BIBF 1120. A reduction of >40% in iAUC/ Ktrans was observed in a considerable number of patients with a maximum (11/35) after 2 cycles (56 days) of treatment. Most of the responders were treated with doses in the range of 250-300mg once daily and 250mg twice daily BIBF 1120. DCE-MRI results suggest an antiangiogenic effect of BIBF 1120.